Expression of p16 in abnormal pap-tests as an indicator of CIN2+ lesions: A possible role in the low grade ASC/US and L/Sil (Ig) cytologic lesions for screening prevention of uterine cervical tumours

Pathologica

Volumn 102, Issue 1, 2010, Pages 6-11

  Passamonti, B ^b   Gustinucci, D ^a   Recchia, P ^b   Bulletti, S ^a   Carlani, A ^a   Cesarini, E ^a   D'Amico, M R ^a   D'Angelo, V ^a   Dato, E D I ^a   Martinelli, N ^a   Malaspina, M ^a   Spita, N ^a  

^a Menarini Diagnostics ^*  (United Kingdom)

^b USL 2   (Italy)

Author keywords

Cin2+ lesion indicator; Citologic lesions; Expression of p16; Progression factor

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ARTICLE; DISEASE COURSE; FEMALE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PREGNANCY; REPRODUCIBILITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR;

BIOLOGICAL MARKERS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; FEMALE; HUMANS; PREGNANCY; REPRODUCIBILITY OF RESULTS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 77952369508     PISSN: 00312983     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19
3. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papilloma virus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
4. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Eng J Med 1998;338:423-428
5. Solomon D, Schiffman M, Tarone R; ALTS Study group Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-299
6. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-698
7. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16 (INK4a) as a specific marker for dysplastic and neoplastic epithelial colls of the cervix uteri. Int J Cancer 2001;92:276-284
8. INK4a antigen in thinlayer, liquid-based specimens. Acta Cytol 2002;46:25-29
9. INK4a as an adjunct in liquid-based cytology. Anal Quant Cytol Histol 2003;25:8-11.
10. Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid comparathed with conventional cytology: a systematic review and meta-analisis. European Guidelines for Quality Assurance in Cervical Cancer Screening. European Network for Cervical Cancre Screening Munich, 2004.
11. Obwegeser JH, Brack S. Does liquid-based technology really improve detection of cervical neoplasia? A prospective, randomized trial comparing the ThinPrep Pap Test with the conventional Pap Test, including follow-up of HSIL case. Acta Cytol 2001;45:709-714
12. Davey E, Barrat A, Irwig L, Chan SF, Macaskill P, Mannes P, et al. Effect of studi design and quality on unsatisfactory rates, cytology classification, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 2006;367:122-132
13. INK4a immunocytochemistry in liquid-based cervico-vaginal specimens with modified Papanicolau counterstaining. J Clin Pathol 2006;0:jpc2005.030726v1.
14. INK4a as specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-284
15. INK4a expression correlates with degree of cervical neoplasia: a comparation with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 2003;16:665-673
16. Carozzi F, Cecchini S, Confortini M, Beccatini V, Cariaggi MP et al. Role of p16(INK4a) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology. Cancer 2006;108:119-123
17. von Knebel Doeberitz M, Wentzensen N, von Knebel Doeberitz C. Biomarkers in screening of cervical cancer in modern gyneco logical cytopathology. In: Meisels A, Morin C. Modern Uterine Cytopathology: Moving to the molecular smear. Chapter twelve. ASCP Press 2007, pp. 227-246.
18. Lea JS, Coleman R, Kurien A, Schorge J, Schorge JO, Miller DS, Minna JD, et al. Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. Am J Obstet Gynecol 2004;190:674-679
19. Stoler MH, Schiffmann M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-1505